Quick Answer
Sionna Therapeutics, Inc. reported Net Income of -$75.27 million for fiscal year 2025.
Sionna Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$75.27M | -22.0% |
| 2024 | -$61.69M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.28M | +20.3% | -12.2% |
| June 30, 2025 | -$18.07M | -111.3% | -9.6% |
| March 31, 2025 | -$16.48M | -39.1% | +35.2% |
| September 30, 2024 | -$25.44M | — | -197.5% |
| June 30, 2024 | -$8.55M | — | +27.8% |
| March 31, 2024 | -$11.85M | — | — |
- Sionna Therapeutics, Inc. showed a decrease of -22.0% in Net Income compared to the prior fiscal year.
- Over the 2024–2025 period, Sionna Therapeutics, Inc.’s net income has declined by 22.0% (from -$61.69 million to -$75.27 million).
- The most recent figure is from Sionna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: